Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380013 | 1.00 | MAPK1 (0.40) | MAPK1SMN1; SMN2TSHRPKMACHE | |
| SCHEMBL22323948 | 0.94 | PTGS1 (0.40) | MAPK1SMN1; SMN2TSHRACHEKDM4E | |
| SCHEMBL29447055 | 0.78 | KDM4E (0.46) | KDM4E | |
| SCHEMBL22324505 | 0.78 | KDM4E (0.46) | KDM4E | |
| SCHEMBL22323971 | 0.76 | CSF1R (0.36) | MAPK1ACHEKDM4EMAPTMEN1 | |
| SCHEMBL29380606 | 0.74 | CSF1R (0.36) | MAPK1ACHEKDM4EMAPTMEN1 | |
| SCHEMBL22323706 | 0.74 | CSF1R (0.36) | MAPK1ACHEKDM4EMAPTMEN1 | |
| SCHEMBL21591469 | 0.71 | ACHE (0.41) | MAPK1SMN1; SMN2ACHEKDM4EMAPT | |
| SCHEMBL22323779 | 0.71 | ALOX15 (0.47) | MAPK1SMN1; SMN2TSHRPKMACHE | |
| SCHEMBL29379822 | 0.71 | ALOX15 (0.47) | MAPK1SMN1; SMN2TSHRPKMACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192454-B1 | AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SKYHAWK THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230331718-A1 | COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331718-A1 | COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4192454-A1 | COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116171153-A | Compositions for modulating splicing | 斯基霍克疗法公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022031838-A1 | COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3920926-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163541-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331718-A1 | COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPE | MAPK1 3343/4885SMN1; SMN2 106/4885TSHR 4181/4885 |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | MAPK1 3842/4885SMN1; SMN2 123/4885TSHR 4288/4885 |
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | MAPK1 3847/4885SMN1; SMN2 237/4885TSHR 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.